DNA

The 3D-Flow Architecture Breakthrough: A Universal, Scalable Digital Processor for Real-Time Pattern Recognition in High-Rate Data Streams — A Platform to Save Millions of Lives and Billions of Euros

A Revolutionary ATCA/VME/VXI 3D-Flow Board: 512 Channels, >2,800 Programmable Operations—Scalable to >50,000 Operations on Each Dataset Arriving Every 25 ns…

1 day ago

Altamira Therapeutics Announces Market Approval of Bentrio Nasal Spray in China

Regulatory clearance of Bentrio in allergic rhinitis for Mainland ChinaNearly 200 million Chinese estimated to suffer from allergic rhinitisBentrio to…

3 days ago

Glioblastoma Foundation Expands Scientific Leadership as It Prepares to Accept Patient Samples for Universal Genomic Testing

Foundation to offer universal genomic testing for glioblastoma patients DURHAM, NC / ACCESS Newswire / December 18, 2025 / Today,…

4 days ago

Co-Diagnostics Joint Venture, CoSara, Invited to Participate in 2nd Advanced TB Diagnostics Course in Chennai, India

SALT LAKE CITY, Dec. 18, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a…

4 days ago

Co-Diagnostics Joint Venture, CoSara, Invited to Participate in 2nd Advanced TB Diagnostics Course in Chennai, India

SALT LAKE CITY, Dec. 18, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a…

4 days ago

Actuate Therapeutics Phase 2 Metastatic Pancreatic Cancer Data Selected for Oral and Poster Presentation at ASCO GI 2026

CHICAGO and FORT WORTH, Texas, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”),…

4 days ago

Aprea Therapeutics CEO Issues Letter to Shareholders Highlighting Pipeline Progress in 2025 and Outlook for 2026

DOYLESTOWN, Pa., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical…

4 days ago

Telomir Pharmaceuticals Reports Favorable IND-Enabling GLP Safety Results for Telomir-1 Supporting First-in-Human Clinical Development

No treatment-related adverse toxicity was observed across completed GLP studies, with consistent systemic exposure following oral administration. MIAMI, FL /…

4 days ago

Telomir Pharmaceuticals Reports Favorable IND-Enabling GLP Safety Results for Telomir-1 Supporting First-in-Human Clinical Development

No treatment-related adverse toxicity was observed across completed GLP studies, with consistent systemic exposure following oral administration. MIAMI, FL /…

4 days ago

Akari Therapeutics Releases Virtual Investor “What This Means” Segment

Watch the “What This Means” video here TAMPA, Fla. and LONDON, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc…

4 days ago